Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Tam, Constantine S., Opat, Stephen, Simpson, David, Cull, Gavin, Munoz, Javier, Phillips, Tycel J., Kim, Won Seog, Rule, Simon, Atwal, Siminder Kaur, Wei, Rachel, Novotny, William, Huang, Jane, Wang, Michael, Trotman, Judith
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2021
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270663/
https://ncbi.nlm.nih.gov/pubmed/34152395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020004074
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge